GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal transition
| Autor: | Jing-Jing Liu, Xue-Min Yao, Min Fu, Liang Kong, Fu-Yi Cai, Feng-Ju Niu, Si-Yu He, Xin-Ze Liu, Rui-Jun Ju, Xue-Tao Li, Ming Jing, Lu Zhang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Epithelial-Mesenchymal Transition
Daunorubicin Pharmaceutical Science Breast Neoplasms 02 engineering and technology Diosgenin 030226 pharmacology & pharmacy Metastasis 03 medical and health sciences 0302 clinical medicine Breast cancer Targeted liposomes Cell Line Tumor Drug Discovery medicine Humans Epithelial–mesenchymal transition Pharmacology Liposome Transition (genetics) Chemistry Organic Chemistry 021001 nanoscience & nanotechnology medicine.disease Liposomes Cancer research 0210 nano-technology medicine.drug |
| Zdroj: | Drug development and industrial pharmacy. 46(6) |
| ISSN: | 1520-5762 |
| Popis: | Tumor invasion and metastasis are the nodus of anti-tumor. Epithelial cell–mesenchymal transition is widely regarded as one of the key steps in the invasion and metastasis of breast cancer. In this study, GGP modified daunorubicin plus dioscin liposomes are constructed and characterized. GGP modified daunorubicin plus dioscin liposome has suitable particle size, narrow PDI, zeta potential of about –5 mV, long cycle effect, and enhanced cell uptake due to surface modification of GGP making the liposome could enter the inside of the tumor to fully exert its anti-tumor effect. The results of in vitro experiments show that the liposome has superior killing effect on tumor cells and invasion. In vivo results indicate that the liposome prolongs the drug’s prolonged time in the body and accumulates at the tumor site with little systemic toxicity. In short, the targeted liposome can effectively inhibit tumor invasion and may provide a new strategy for the treatment of invasive breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|